What are analysts'forecasts for CRISPR Therapeutics'stock?
20 brokers have issued twelve-month price objectives for CRISPR Therapeutics' shares. Their forecasts range from $110.00 to $210.00. On average, they anticipate CRISPR Therapeutics' share price to reach $157.67 in the next year. This suggests a possible upside of 27.3% from the stock's current price.
How much of CRISPR Therapeutics'stock is owned by institutions?
51.94% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Earnings for CRISPR Therapeutics are expected to decrease in the coming year, from $5.00 to ($7.27) per share.
How does CRISPR Therapeutics's PE ratio compare to its medical peers?
The P/E ratio of CRISPR Therapeutics is 14.24, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 14.10. CRISPR Therapeutics has a P/B Ratio of 2.90.
Is CRSP stock a good Buy?
Out of 14 analysts, 4 (28.57%) are recommending CRSP as a Strong Buy, 5 (35.71%) are recommending CRSP as a Buy, 5 (35.71%) are recommending CRSP as a Hold, 0 (0%) are recommending CRSP as a Sell, and 0 (0%) are recommending CRSP as a Strong Sell.
What will CRSP stock be worth in 2025?
CRISPR Technologies: 191,416% implied sales growth by 2025 CRISPR Therapeutics (CRSP -0.17%), a company leaning on gene-editing technology to precisely alter genomic DNA and tackle hard-to-treat diseases, is expected to see sales climb from $719,000 in 2020 to a consensus of $1.377 billion by 2025.
What is Target price for CRISPR?
Stock Price TargetsHigh$220.00Median$108.50Low$46.00Average$112.41Current Price$79.95
Is CRSP overpriced?
To conclude, The stock of CRISPR Therapeutics AG (NAS:CRSP, 30-year Financials) is estimated to be significantly overvalued. The company's financial condition is fair and its profitability is poor. Its growth ranks in the bottom 10% of the companies in Biotechnology industry.
What is the best Crispr stock to buy?
5 best CRISPR stocks to buyCompanyMarket CapCRISPR Therapeutics (NASDAQ:CRSP)$6.1 billionEditas Medicine (NASDAQ:EDIT)$1.9 billionIntellia Therapeutics (NASDAQ:NTLA)$8.9 billionVerve Therapeutics (NASDAQ:VERV)$1.9 billion1 more row
Will CRSP go up?
Is CRSP stock going to rise? Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and CRSP is experiencing slight selling pressure.
Is Crispr undervalued?
Valuation metrics show that CRISPR Therapeutics AG may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors.
Why is Crispr stock low?
What happened. Shares of CRISPR Therapeutics (CRSP 0.81%) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.
Whats going on with Crispr?
In November 2020, CRISPR Therapeutics announced early success from their CTX001 therapy, which delivers CRISPR-Cas9 to hematopoietic stem cells via electroporation. After a patient's own hematopoietic stem cells are chemically eliminated with busulfan, the CRISPR-edited stem cells are infused back into the patient.
Is CRISPR Therapeutics profitable?
During the last half decade, CRISPR Therapeutics became profitable. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains.
Who owns CRSP stock?
Top 10 Owners of CRISPR Therapeutics AGStockholderStakeShares ownedBlackRock Fund Advisors2.53%1,962,052Loomis, Sayles & Co. LP1.67%1,290,905Fidelity Management & Research Co...1.63%1,261,622The Vanguard Group, Inc.1.51%1,170,3366 more rows
Why is CRISPR stock low?
What happened. Shares of CRISPR Therapeutics (CRSP 0.81%) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.
Is CRISPR a buy Zacks?
Zacks' proprietary data indicates that CRISPR Therapeutics AG is currently rated as a Zacks Rank 3 and we are expecting an inline return from the CRSP shares relative to the market in the next few months.
Is McDonald's a blue chip stock?
Blue-Chip Stocks to Buy: McDonald's (MCD) First on this list of blue-chip stocks to buy is McDonald's (NYSE:MCD).
What is the forecast for Apple stock?
Stock Price Forecast The 39 analysts offering 12-month price forecasts for Apple Inc have a median target of 185.00, with a high estimate of 219.94 and a low estimate of 130.00. The median estimate represents a +18.10% increase from the last price of 156.65.
Is CRISPR THERAPEUTICS AG Stock a good buy in 2022, according to Wall Street analysts?
The consensus among 12 Wall Street analysts covering ( NASDAQ : CRSP ) stock is to Buy CRSP stock. Out of 12 analysts , 4 ( 33.33% ) are...
What is CRSP's earnings growth forecast for 2022-2024?
( NASDAQ : CRSP ) CRISPR THERAPEUTICS AG 's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology indust...
What is CRSP's revenue growth forecast for 2022-2024?
( NASDAQ : CRSP ) CRISPR THERAPEUTICS AG 's forecast annual revenue growth rate of -11.21% is not forecast to beat the US Biotechnology ind...
What is CRSP's forecast return on assets (ROA) for 2022-2025?
(NASDAQ: CRSP) forecast ROA is 9.84%, which is lower than the forecast US Biotechnology industry average of 21.34%.
What is CRSP's Price Target?
According to 11 Wall Street analyst s that have issued a 1 year CRSP price target, the average CRSP price target is $115.00 , with the high...
What is CRSP's Earnings Per Share (EPS) forecast for 2022-2024?
(NASDAQ: CRSP) CRISPR THERAPEUTICS AG's current Earnings Per Share (EPS) is $4.14. On average, analysts forecast that CRSP's EPS will be -$8.97 for...
What is CRSP's forecast return on equity (ROE) for 2022-2025?
(NASDAQ: CRSP) forecast ROE is 11.42%, which is considered weak.
Stock Price Forecast
Analyst Recommendations
The 20 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 145.00, with a high estimate of 220.00 and a low estimate of 64.00. The median estimate represents a +149.66% increase from the last price of 58.08.
Analyst price target for CRSP
The current consensus among 24 polled investment analysts is to Buy stock in CRISPR Therapeutics AG. This rating has held steady since February, when it was unchanged from a Buy rating. Move your mouse over past months for detail
CRSP earnings per share forecast
Based on 9 analyst s offering 12 month price targets for CRISPR Therapeutics AG.
CRSP revenue forecast
What is CRSP 's earnings per share in the next 3 years based on estimates from 13 analyst s?
CRSP revenue growth forecast
What is CRSP 's revenue in the next 3 years based on estimates from 8 analyst s?
Signals & Forecast
How is CRSP forecast to perform vs Biotechnology companies and vs the US market?
Support, Risk & Stop-loss
There are mixed signals in the stock today. The CRISPR Therapeutics AG stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal.
Is CRISPR Therapeutics AG stock A Buy?
CRISPR Therapeutics AG finds support from accumulated volume at $59.00 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are neutral selling more shares than they are buying in CRISPR Therapeutics AG
CRISPR Therapeutics AG holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Golden Star Signal
In the last 100 trades there were 1.08 million shares bought and 1.39 million shares sold. The last trade was done 9 days ago by Smith Brendan who bough 15.3 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Historical and forecast chart of CRISPR Therapeutics stock
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
CRISPR Therapeutics Daily Price Targets
The chart below shows the historical price of CRISPR Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast.
CRISPR Therapeutics forecast for this year
Forecast target price for 02-26-2022: $ 52.99. Negative dynamics for CRISPR Therapeutics shares will prevail with possible volatility of 3.149%.
CRISPR Therapeutics information and performance
An uptrend is forecast for this month with an optimal target price of $ 65.005. Pessimistic: $59.49. Optimistic: $70.52
Historical and forecast chart of CRISPR Therapeutics stock
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA.
CRISPR Therapeutics information and performance
The chart below shows the historical price of CRISPR Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast.
CRISPR Therapeutics price target for 2021 by month
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA.
